MedTrace Logo

The Efficacy of Huaiqihuang Granule in Children With Primary Nephrotic Syndrome

NCT03332420 · Status: COMPLETED · Type: OBSERVATIONAL · Enrollment: 1507

Last updated 2022-12-22

No results posted yet for this study

Summary

This is a multisite, open-label, prospective and registered study designed to evaluate the efficacy and safety of Huai-Qi-Huang granule in children with primary nephrotic syndrome.

Conditions

  • Nephrotic Syndrome

Sponsors & Collaborators

  • Capital Institute of Pediatrics, China

    collaborator OTHER

  • Qidong Gaitianli Medicines Co., Ltd

    lead INDUSTRY

Principal Investigators

  • Chaoying Chen, Professor · Children's Hospital of The Capital Institute of Pediatrics

Eligibility

Min Age
1 Year
Max Age
18 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2017-11-16
Primary Completion
2021-07-21
Completion
2021-08-31

Countries

  • China

Study Locations

More Related Trials

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT03332420 on ClinicalTrials.gov